LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

TMO

572.75

+1.15%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

TMO

572.75

+1.15%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

TMO

572.75

+1.15%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

TMO

572.75

+1.15%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

TMO

572.75

+1.15%↑

Search

Abbott Laboratories

Затворен

СекторЗдравеопазване

126.19 1.02

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

125.72

Максимум

126.22

Ключови измерители

By Trading Economics

Приходи

454M

1.8B

Продажби

227M

11B

P/E

Средно за сектора

15.558

77.256

EPS

1.3

Дивидентна доходност

1.91

Марж на печалбата

15.967

Служители

114,000

EBITDA

-824M

2.2B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+16.44% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

1.91%

2.33%

Следваща дата на дивидент

17.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-13B

215B

Предишно отваряне

125.17

Предишно затваряне

126.19

Настроения в новините

By Acuity

34%

66%

88 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Abbott Laboratories Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.10.2025 г., 12:02 ч. UTC

Печалби

Abbott Labs Posts Higher 3Q Sales, Reaffirms Outlook

17.07.2025 г., 12:10 ч. UTC

Печалби

Abbott Labs Pares Outlook, Logs 2Q Profit Gains

8.11.2025 г., 18:10 ч. UTC

Печалби

10 Defensive Stocks with Market-Beating Yields -- Barrons.com

30.10.2025 г., 12:38 ч. UTC

Печалби

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

30.10.2025 г., 12:01 ч. UTC

Печалби

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

22.10.2025 г., 19:57 ч. UTC

Придобивния, сливания и поглъщания

Synlait Milk Ltd.: OIO Gives Abbott Consent to Acquire Co's North Island Assets

15.10.2025 г., 16:15 ч. UTC

Печалби

Abbott Stock Drops Despite Earnings. Baby-Formula Sales Took a Hit. -- Barrons.com

15.10.2025 г., 12:25 ч. UTC

Печалби

Abbott Posts Solid Earnings, Adult Nutrition Drives Sales. The Stock Drops Anyway. -- Barrons.com

15.10.2025 г., 11:32 ч. UTC

Печалби

Abbott Labs Still Sees 2025 Organic Sales Up 6%-7% Including Covid-19 Testing-Related Sales >ABT

15.10.2025 г., 11:32 ч. UTC

Печалби

Abbott Labs Still Sees 2025 Organic Sales Up 7.5%-8% Excluding Covid-19 Testing-Related Sales >ABT

15.10.2025 г., 11:31 ч. UTC

Печалби

Abbott Labs Sees 2025 Adj EPS $5.12-Adj EPS $5.18 >ABT

15.10.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 3Q Adjusted Operating Margin 23% >ABT

15.10.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs Reaffirms Full-Year Guidance >ABT

15.10.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 3Q Organic Sales Growth Up 5.5% >ABT

15.10.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 3Q Sales $11.37B >ABT

15.10.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 3Q Adj EPS $1.30 >ABT

15.10.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 3Q Net $1.64B >ABT

15.10.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 3Q EPS 94c >ABT

11.10.2025 г., 00:18 ч. UTC

Придобивния, сливания и поглъщания

Why Biotech May Be Back -- Barrons.com

17.07.2025 г., 13:14 ч. UTC

Печалби

Abbott Labs Stock Falls After Earnings. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17.07.2025 г., 12:16 ч. UTC

Печалби

Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17.07.2025 г., 11:32 ч. UTC

Печалби

Abbott Labs Sees 3Q Adj EPS $1.28-Adj EPS $1.32 >ABT

17.07.2025 г., 11:32 ч. UTC

Печалби

Abbott Labs: See Momentum Carrying Into 2026 >ABT

17.07.2025 г., 11:31 ч. UTC

Печалби

Abbott Labs Sees 2025 Organic Sales Up 7.5%-8%, Excluding Covid-19 Testing-Related Sales >ABT

17.07.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 2Q Organic Sales Rose 6.9% >ABT

17.07.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 2Q Adjusted Operating Margin 22.9% >ABT

17.07.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 2Q Adjusted Gross Margin 57% >ABT

17.07.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 2Q Organic Sales Growth Up 6.9% >ABT

17.07.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 2Q Sales $11.14B >ABT

17.07.2025 г., 11:30 ч. UTC

Печалби

Abbott Labs 2Q Net $1.78B >ABT

Сравнение с други в отрасъла

Ценова промяна

Abbott Laboratories Прогноза

Ценова цел

By TipRanks

16.44% нагоре

12-месечна прогноза

Среден 147.13 USD  16.44%

Висок 162 USD

Нисък 136 USD

Според 19 анализатори от Wall Street, предложили 12-месечна ценова цел за Abbott Laboratories през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

19 ratings

17

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

132.82 / 134.43Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Neutral Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

88 / 374 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
help-icon Live chat